ENHERTU Plus Pertuzumab Achieves Priority Review—DESTINY-Breast09 Data Signals Potential Shift in 1st-Line HER2-Positive Metastatic Breast Cancer Care

DESTINY-Breast09 Trial Sets New Landmark for Progression-Free Survival

AstraZeneca and Daiichi Sankyo’s ENHERTU, in combination with pertuzumab, has taken a major step forward as a first-line therapy for patients with HER2-positive metastatic breast cancer. The U.S. FDA has granted Priority Review for this regimen based on data from the DESTINY-Breast09 Phase III trial—results that show a significant 44% reduction in risk of disease progression or death compared to the long-standing standard THP (taxane, trastuzumab, and pertuzumab) approach. If approved, this therapy could represent the first substantial advance in the field in over a decade.

Key Data: Median Progression-Free Survival Surpasses Three Years

The most striking result from DESTINY-Breast09 was the leap in median progression-free survival (PFS)—40.7 months with ENHERTU plus pertuzumab, compared to 26.9 months for THP. That means patients receiving the new combination experienced a median PFS of more than three years, offering hope for prolonged disease control.

The study also highlighted improvements across multiple efficacy measures. The objective response rate (ORR) reached 85.1% for the ENHERTU plus pertuzumab arm, versus 78.6% with THP. Complete response (CR) rates more than doubled: 58 patients achieved a CR with the new therapy compared to 33 with THP.

FDA Priority Review Reflects Major Clinical Need

The FDA grants Priority Review to treatments that promise a marked improvement over available options. The review process—set to conclude with an action date in the first quarter of 2026—signals the regulator’s view that ENHERTU plus pertuzumab could meet a significant unmet medical need in HER2-positive metastatic breast cancer, which affects approximately 10,000 U.S. patients in the 1st-line metastatic setting annually.

This development follows the FDA’s recent Breakthrough Therapy Designation for the regimen and leverages the Real-Time Oncology Review program, designed to speed potentially transformative cancer treatments to patients sooner.

Expert Perspective: "First Major Evolution in Treatment in More Than a Decade"

Dr. Susan Galbraith, AstraZeneca’s Executive Vice President, Oncology R&D, described the findings as a "landmark": “The DESTINY-Breast09 trial showed that treating patients...produced a new landmark of more than 40 months for progression-free survival and nearly doubled the number of patients with no evidence of disease on imaging.” She added this could represent the first meaningful advance in the field since the previous standard was established.

Safety Profile in Line with Known Therapies

The safety results were consistent with prior findings for each agent, and no new concerns emerged. However, clinicians are advised to remain vigilant for key risks such as interstitial lung disease/pneumonitis and embryo-fetal toxicity—warnings highlighted in prescribing information for ENHERTU. Most common side effects included reduced white blood cell count (up to 75%), nausea (up to 76%), and fatigue (up to 59%), as reflected in multiple large studies across breast and other cancer populations.

Table: Most Common Adverse Reactions in Breast Cancer Studies

Broader Impact: A Step Toward Redefining the Standard of Care

ENHERTU is already approved as a 2nd-line therapy in more than 85 countries based on strong efficacy data. Its potential move into the 1st-line setting could raise the bar for initial management of HER2-positive metastatic breast cancer, offering patients longer remission and improved outcomes.

While safety vigilance is essential, the significant improvements in both survival and response rates set the stage for a possible new standard—one that may transform first-line care if regulatory approval follows as expected in early 2026.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI